Ryvu Therapeutics (9Y4) Stock Overview
A clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
9Y4 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Ryvu Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł3.43 |
| 52 Week High | zł7.25 |
| 52 Week Low | zł3.11 |
| Beta | 0.42 |
| 1 Month Change | -0.72% |
| 3 Month Change | -40.04% |
| 1 Year Change | -52.29% |
| 3 Year Change | -74.05% |
| 5 Year Change | -72.52% |
| Change since IPO | -68.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9Y4 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 1.8% | 10.2% | 0.7% |
| 1Y | -52.3% | 0.4% | 0.6% |
Return vs Industry: 9Y4 underperformed the German Life Sciences industry which returned 1.4% over the past year.
Return vs Market: 9Y4 underperformed the German Market which returned 0.5% over the past year.
Price Volatility
| 9Y4 volatility | |
|---|---|
| 9Y4 Average Weekly Movement | 9.0% |
| Life Sciences Industry Average Movement | 8.0% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 9Y4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9Y4's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 228 | Pawel Przewiezlikowski | ryvu.com |
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia.
Ryvu Therapeutics S.A. Fundamentals Summary
| 9Y4 fundamental statistics | |
|---|---|
| Market cap | €81.87m |
| Earnings (TTM) | -€20.51m |
| Revenue (TTM) | €20.45m |
Is 9Y4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9Y4 income statement (TTM) | |
|---|---|
| Revenue | zł88.38m |
| Cost of Revenue | zł15.22m |
| Gross Profit | zł73.16m |
| Other Expenses | zł161.76m |
| Earnings | -zł88.60m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Sep 17, 2026
| Earnings per share (EPS) | -3.83 |
| Gross Margin | 82.77% |
| Net Profit Margin | -100.25% |
| Debt/Equity Ratio | 229.4% |
How did 9Y4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/15 09:26 |
| End of Day Share Price | 2026/07/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ryvu Therapeutics S.A. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Jonas Peciulis | Edison Investment Research |
| Dariusz Gorski | Erste Bank Polska S.A. |